


Details:
One of co-primary endpoints of study on adjunctive Rexulti (brexpiprazole) in adults with MDD and inadequate response to ADT was new exploratory outcome focusing on positive health aspects across emotional, physical, social, and cognitive domains.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck AS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022